Drugs / DCR-MYC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02110563 | Apr 2014 → Oct 2016 | non-Hodgkin lymphoma, pancreatic neuroendocrine tumor, plasma cell myeloma | Dicerna Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02314052 | Jan 2015 → Oct 2016 | hepatocellular carcinoma | Dicerna Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCR-MYC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314052 ↗ |
| Action | Inhibit | “ability to inhibit MYC” NCT02110563 ↗ |
| Modality | Small interfering RNA (siRNA) | “Small Inhibitory RNA (siRNA) Oligonucleotide” NCT02110563 ↗ |
| Route | Intravenous | “administered by 2 hour intravenous (IV) infusion” NCT02110563 ↗ |
| Target | MYC | “targets the oncogene MYC” NCT02110563 ↗ |